Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GIMEMA AML 8A trial

Authors :: Keating, S.
Suciu, S.
Witte, T.J.M. de
Mandelli, F.
Willemze, R.
Resegotti, L.
Broccia, G.
Thaler, J.
Labar, B.
Damasio, E.
Bizzi, B.
Rotoli, B.
Vekhoff, A.
Muus, P.
Petti, M.C.
Dardenne, M.
Solbu, G.
Vegna, M.L.
Zittoun, R.
Source :: Bone Marrow Transplantation, IV, 993-1001, Bone Marrow Transplantation, 17, iss, 6, pp. 993-1001, Bone Marrow Transplantation, IV, pp. 993-1001, Bone Marrow Transplantation, 17, 993-1001
Publication Year :: 1996
Abstract: Contains fulltext : 22795___.PDF (Publisher’s version ) (Open Access)

Subjects :: clonal remission after intensive antileukemic therapy (Biomed-2 1995) [European evaluation of intensive antileukemic therapy for patients with myelodysplastic syndrome (MDS) CRIANT]

Tools